Department of Nutrition, University of Tennessee Knoxville , Knoxville, TN, USA.
Tennessee Agricultural Experiment Station, University of Tennessee Institute of Agriculture , Knoxville, TN, USA.
Adipocyte. 2020 Dec;9(1):454-471. doi: 10.1080/21623945.2020.1803642.
The prevalence of obesity and its comorbidities has sparked a worldwide concern to address rates of adipose tissue accrual. Recent studies have demonstrated a novel role of Zyflamend, a blend of natural herbal extracts, in regulating lipid metabolism in several cancer cell lines through the activation of the AMPK signalling pathway. Yet, the role of Zyflamend in adipogenic differentiation and lipid metabolism remains largely unexplored. The objective of this study is to investigate the effects of Zyflamend on white 3T3-MBX pre-adipocyte differentiation and elucidate the molecular mechanisms. We demonstrate that Zyflamend treatment altered cell cycle progression, attenuated proliferation, and increased cell death of 3T3-MBX pre-adipocytes. In addition, treatment with Zyflamend inhibited lipid accumulation during the differentiation of 3T3-MBX cells, consistent with decreased expression of lipogenic genes and increased lipolysis. Mechanistically, Zyflamend-induced alterations in adipogenesis were mediated, at least in part, through the activation of AMPK, PKA, and JNK. Inhibition of AMPK partially reversed Zyflamend-induced inhibition of differentiation, whereas the inhibition of either JNK or PKA fully restored adipocyte differentiation and decreased lipolysis. Taken together, the present study demonstrates that Zyflamend, as a novel anti-adipogenic bioactive mix, inhibits adipocyte differentiation through the activation of the PKA and JNK pathways.
7-AAD: 7-amino-actinomycin D; ACC: acetyl-CoA carboxylase; AKT: protein kinase B; AMPK: AMP-activated protein kinase; ATGL: adipose triglyceride lipase; C/EBPα: CCAAT-enhancer binding protein alpha; DMEM: Dulbecco's Modified Eagle Medium; DMSO: dimethyl sulphoxide; DTT: dithiothreitol; EGTA: ethylene glycol-bis-(2-aminoethyl)-N,N,N',N'-tetraacetic acid; ERK: extracellular signal-regulated kinases; FASN: fatty acid synthase; FBS: foetal bovine serum; GLUT: glucose transporter; HSL: hormone-sensitive lipase; IR: insulin receptor; IRS: insulin receptor substrate; JNK: c-JUN N-terminal kinase; MGL: monoacylglycerol lipase; NaF: sodium fluoride; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; PBS: phosphate buffered- saline; PCB: pyruvate carboxylase; PDE: phosphodiesterase; PKA: protein kinase cAMP-dependent; PMSF: phenylmethylsulfonyl fluoride; PPARγ: perilipin peroxisome proliferator-activated receptor gamma; PREF-1: pre-adipocyte factor 1; PVDF: polyvinylidene fluoride; RIPA: radio-immunoprecipitation assay; SDS-PAGE: sodium dodecyl sulphate polyacrylamide gel electrophoresis; SEM: standard error of the mean; SOX9: suppressor of cytokine signalling 9; TGs: triacylglycerols.
肥胖及其合并症的流行引起了全球关注,以解决脂肪组织积累的速度。最近的研究表明,Zyflamend(一种天然草药提取物的混合物)在通过激活 AMPK 信号通路调节几种癌细胞系中的脂质代谢方面具有新的作用。然而,Zyflamend 在脂肪生成分化和脂质代谢中的作用在很大程度上仍未得到探索。本研究旨在探讨 Zyflamend 对白色 3T3-MBX 前脂肪细胞分化的影响,并阐明其分子机制。我们证明 Zyflamend 处理改变了 3T3-MBX 前脂肪细胞的细胞周期进程,减弱了增殖并增加了细胞死亡。此外,Zyflamend 处理抑制了 3T3-MBX 细胞分化过程中的脂质积累,这与脂肪生成基因的表达降低和脂肪分解增加一致。在机制上,Zyflamend 诱导的脂肪生成改变至少部分是通过 AMPK、PKA 和 JNK 的激活介导的。AMPK 的抑制部分逆转了 Zyflamend 诱导的分化抑制,而 JNK 或 PKA 的抑制完全恢复了脂肪细胞分化并减少了脂肪分解。总之,本研究表明,作为一种新型的抗脂肪生成生物活性混合物,Zyflamend 通过激活 PKA 和 JNK 途径抑制脂肪细胞分化。